<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04728139</url>
  </required_header>
  <id_info>
    <org_study_id>colorectal cancer</org_study_id>
    <nct_id>NCT04728139</nct_id>
  </id_info>
  <brief_title>Assessment of Glypican 3 as Apredictive Marker in Colorectal Cancer Patients</brief_title>
  <official_title>Assessment of Glypican 3 as a Predictive Marker in Colorectal Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  Evaluation Of Glypican 3 in serum of colorectal cancer patients .&#xD;
&#xD;
        -  Correlation between Glypican 3 and clinicopathological characteristics of colorectal&#xD;
           cancer .&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Colorectal cancer (CRC) is the third most common malignancy and the fourth most prominent&#xD;
      cause of cancer-related deaths worldwide. Also it is the 7th commonest cancer in Egypt,&#xD;
      representing 3.47% of male cancers and 3% of female cancers.The Glypicans , a family of&#xD;
      proteins classified as HSPGs (heparan sulfate proteoglycan) , have been shown to interact&#xD;
      with a number of growth factors and modulate growth factor activity and are linked to the&#xD;
      xtracellular side of cell membrane by a glycosylphosphatidylinositol (GPI) anchor . Members&#xD;
      of this large family of transmembrane proteins have been identified in both mammals and&#xD;
      drosophila: 6 glypicans (GPC-1 through GPC-6) in mammals, and two others in the fly&#xD;
      .Glypican-3 (GPC3) as one of this family is a protein of about 70 kD . It has multiple sugar&#xD;
      chains and heparan sulfate modification sites . These proteins (Glypicans) participate in&#xD;
      organ development by modulating extracellular growth signals and morphogen gradient&#xD;
      formation, and are involved in human overgrowth and skeletal dysplasia problems .In some&#xD;
      cancers, they are highly expressed, associated with tumorigenesis, and regulating&#xD;
      angiogenesis for cancer progression and invasion . Abnormal expression of glypicans has been&#xD;
      noted in multiple types of cancer. For examples, GPC-1 expression was found to be increased&#xD;
      in breast cancer tissues and ovarian malignant tumors .GPC-2 is associated with neuroblastoma&#xD;
      .Expression of GPC-3 was found in high-grade urothelial carcinoma and also reported in some&#xD;
      non-CNS tumors of the brain.There have been several reports about the clinical usefulness of&#xD;
      the N-terminal form of GPC3. Enzyme-linked immunosorbent assay methods capable of detecting&#xD;
      the N-terminal form of GPC3 . A study of colorectal cancer tissue speciment shows a&#xD;
      correlation between expression of GPC3 with the clinicopathologic variables such as the level&#xD;
      of differentiation, GPC3 was found to be expressed in ( 42.8% ) of the well-differentiated&#xD;
      tumors, and (50%) of the moderately differentiated tumors, (75%) of the moderately and poorly&#xD;
      differentiated tumors .Therefore, it was found that the expression of GPC3 was correlated&#xD;
      with the pathological grade of the tumors .&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2021</start_date>
  <completion_date type="Anticipated">October 2024</completion_date>
  <primary_completion_date type="Anticipated">September 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of Glypican 3 role as a predictive and diagnostic marker of colorectal marker .</measure>
    <time_frame>3 years</time_frame>
    <description>measurment of GLYPICAN 3 level in serum of colorectal patients using ELISA method</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Addition of Glypican 3 to the routine markers of colorectal cancer . - Correlatin of this marker with the disease pathology and management procedures .</measure>
    <time_frame>3 years</time_frame>
    <description>measurment of GLYPICAN 3 level in serum of colorectal patients using ELISA method</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>patients with colorecta cancer</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy individuals</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>glypican 3</intervention_name>
    <description>Assessment of glypican 3 presence in colorectal cancer patients using ELISA</description>
    <arm_group_label>patients with colorecta cancer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with colorectal cancer and admitted to south egypt cancer institute .&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other malignant diseases .&#xD;
&#xD;
          -  Patients received chemotherapy for colorectal cancer .&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Reham Hany Mohammed</last_name>
    <phone>01118441744</phone>
    <email>rehamhany809@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hosney Badrawy Hamed</last_name>
    <phone>01060664976</phone>
    <email>BadranH@yahoo.com</email>
  </overall_contact_backup>
  <reference>
    <citation>TerziÄ‡ J, Grivennikov S, Karin E, Karin M. Inflammation and colon cancer. Gastroenterology. 2010 Jun;138(6):2101-2114.e5. doi: 10.1053/j.gastro.2010.01.058. Review.</citation>
    <PMID>20420949</PMID>
  </reference>
  <reference>
    <citation>Ibrahim AS, Khaled HM, Mikhail NN, Baraka H, Kamel H. Cancer incidence in egypt: results of the national population-based cancer registry program. J Cancer Epidemiol. 2014;2014:437971. doi: 10.1155/2014/437971. Epub 2014 Sep 21.</citation>
    <PMID>25328522</PMID>
  </reference>
  <reference>
    <citation>Ijaz B, Formentin E, Ronci B, Locato V, Barizza E, Hyder MZ, Lo Schiavo F, Yasmin T. Salt tolerance in indica rice cell cultures depends on a fine tuning of ROS signalling and homeostasis. PLoS One. 2019 Apr 30;14(4):e0213986. doi: 10.1371/journal.pone.0213986. eCollection 2019.</citation>
    <PMID>31039145</PMID>
  </reference>
  <reference>
    <citation>Filmus J, Selleck SB. Glypicans: proteoglycans with a surprise. J Clin Invest. 2001 Aug;108(4):497-501. Review.</citation>
    <PMID>11518720</PMID>
  </reference>
  <reference>
    <citation>Shirakawa H, Kuronuma T, Nishimura Y, Hasebe T, Nakano M, Gotohda N, Takahashi S, Nakagohri T, Konishi M, Kobayashi N, Kinoshita T, Nakatsura T. Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer. Int J Oncol. 2009 Mar;34(3):649-56.</citation>
    <PMID>19212669</PMID>
  </reference>
  <reference>
    <citation>Sarrazin S, Lamanna WC, Esko JD. Heparan sulfate proteoglycans. Cold Spring Harb Perspect Biol. 2011 Jul 1;3(7). pii: a004952. doi: 10.1101/cshperspect.a004952. Review.</citation>
    <PMID>21690215</PMID>
  </reference>
  <reference>
    <citation>Fico A, Maina F, Dono R. Fine-tuning of cell signaling by glypicans. Cell Mol Life Sci. 2011 Mar;68(6):923-9. Epub 2011 Feb 22. Review.</citation>
    <PMID>18087675</PMID>
  </reference>
  <reference>
    <citation>Matsuda K, Maruyama H, Guo F, Kleeff J, Itakura J, Matsumoto Y, Lander AD, Korc M. Glypican-1 is overexpressed in human breast cancer and modulates the mitogenic effects of multiple heparin-binding growth factors in breast cancer cells. Cancer Res. 2001 Jul 15;61(14):5562-9.</citation>
    <PMID>11454708</PMID>
  </reference>
  <reference>
    <citation>Davies EJ, Blackhall FH, Shanks JH, David G, McGown AT, Swindell R, Slade RJ, Martin-Hirsch P, Gallagher JT, Jayson GC. Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer. Clin Cancer Res. 2004 Aug 1;10(15):5178-86.</citation>
    <PMID>15297422</PMID>
  </reference>
  <reference>
    <citation>Bosse KR, Raman P, Zhu Z, Lane M, Martinez D, Heitzeneder S, Rathi KS, Kendsersky NM, Randall M, Donovan L, Morrissy S, Sussman RT, Zhelev DV, Feng Y, Wang Y, Hwang J, Lopez G, Harenza JL, Wei JS, Pawel B, Bhatti T, Santi M, Ganguly A, Khan J, Marra MA, Taylor MD, Dimitrov DS, Mackall CL, Maris JM. Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk Neuroblastoma. Cancer Cell. 2017 Sep 11;32(3):295-309.e12. doi: 10.1016/j.ccell.2017.08.003.</citation>
    <PMID>28898695</PMID>
  </reference>
  <reference>
    <citation>Aleksikova RIa. [On the morbidity of school-children in senior classes of Leningrad boarding schools]. Zdravookhr Ross Fed. 1965 Nov;9(11):11-3. Russian.</citation>
    <PMID>4225756</PMID>
  </reference>
  <reference>
    <citation>Chan ES, Pawel BR, Corao DA, Venneti S, Russo P, Santi M, Sullivan LM. Immunohistochemical expression of glypican-3 in pediatric tumors: an analysis of 414 cases. Pediatr Dev Pathol. 2013 Jul-Aug;16(4):272-7. doi: 10.2350/12-06-1216-OA.1. Epub 2013 Mar 26.</citation>
    <PMID>23530909</PMID>
  </reference>
  <reference>
    <citation>Haruyama Y, Yorita K, Yamaguchi T, Kitajima S, Amano J, Ohtomo T, Ohno A, Kondo K, Kataoka H. High preoperative levels of serum glypican-3 containing N-terminal subunit are associated with poor prognosis in patients with hepatocellular carcinoma after partial hepatectomy. Int J Cancer. 2015 Oct 1;137(7):1643-51. doi: 10.1002/ijc.29518. Epub 2015 Apr 6.</citation>
    <PMID>25784484</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>September 13, 2020</study_first_submitted>
  <study_first_submitted_qc>January 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 28, 2021</study_first_posted>
  <last_update_submitted>February 3, 2021</last_update_submitted>
  <last_update_submitted_qc>February 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Reham Hany Mohammed</investigator_full_name>
    <investigator_title>residet doctor</investigator_title>
  </responsible_party>
  <keyword>glypican 3</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <study_docs>
    <study_doc>
      <doc_type>Study Protocol</doc_type>
      <doc_url>http://rehamhany809@gmail.com</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

